Biomarker Analysis Publication Highlights Key Signals Of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder Attacks, Illustrates Efficacy Of UPLIZNA
Portfolio Pulse from Happy Mohamed
Horizon Therapeutics (NASDAQ:HZNP) announced new data from the Phase 3 N-MOmentum pivotal trial of UPLIZNA, which shows the drug's efficacy in reducing biomarker levels associated with Neuromyelitis Optica Spectrum Disorder (NMOSD) attacks and disability worsening. The results were published in The Journal of Neurology, Neurosurgery and Psychiatry.
June 01, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Horizon Therapeutics' UPLIZNA Phase 3 N-MOmentum trial data demonstrates efficacy in reducing biomarkers associated with NMOSD attacks and disability worsening, potentially boosting the drug's market potential.
The positive results from the Phase 3 N-MOmentum trial of UPLIZNA demonstrate the drug's efficacy in reducing biomarkers associated with NMOSD attacks and disability worsening. This could lead to increased demand for the drug and potentially boost Horizon Therapeutics' market potential, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100